SEC Filings

Form 10-Q
PDS BIOTECHNOLOGY CORP filed this Form 10-Q on 05/14/2019
Document Outline
Entire Document (3097.6 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - SECURITIES AND EXCHANGE COMMISSION
Page 2 - PDS BIOTECHNOLOGY CORPORATION
Page 3 - As previously disclosed, on March 15, 2019, PDS Biotechnology Corporation (f/k/a Edge Therapeutics,
Page 4 - PART 1. FINANCIAL INFORMATION
Page 5 - PDS BIOTECHNOLOGY CORPORATION
Page 6 - PDS BIOTECHNOLOGY CORPORATION
Page 7 - PDS BIOTECHNOLOGY CORPORATION
Page 8 - PDS Biotechnology Corporation
Page 9 - N/A
Page 10 - N/A
Page 11 - Note 3 Reverse Merger
Page 12 - Preliminary Purchase Price Allocation
Page 13 - Note 4 Fair Value of Financial Instruments
Page 14 - Note 7 Accrued Expenses and Restructuring Reserve
Page 15 - Note 10 Income Taxes
Page 16 - Note 11 Commitments and Contingencies
Page 17 - Note 12 Related Party Transactions
Page 18 - Note 13 Subsequent Events
Page 19 - ITEM 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 20 - Corporate Information
Page 21 - KEY COMPONENTS OF OUR STATEMENT OF OPERATIONS
Page 22 - Other income (expense), net
Page 23 - Operating Capital Requirements
Page 24 - ITEM 3:QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
Page 25 - PART II. OTHER INFORMATION
Page 26 - We have incurred significant losses since our inception and expect to continue to incur significant
Page 27 - We are dependent on the success of PDS0101, which is still in early-stage clinical development, and
Page 28 - Raising additional funds by issuing securities may cause dilution to existing stockholders, and rais
Page 29 - If we fail to obtain or maintain adequate coverage and reimbursement for PDS0101, our ability to gen
Page 30 - Our business and operations would suffer in the event of system failures.
Page 31 - Risks Related to Clinical Development, Regulatory Approval and Commercialization
Page 32 - Enrollment and retention of subjects in clinical trials is an expensive and time-consuming process a
Page 33 - PDS0101 may cause adverse effects or have other properties that could delay or prevent its regulator
Page 34 - Even if we obtain FDA approval in the United States, we may never obtain approval for or commerciali
Page 35 - Even if PDS0101 receives marketing approval, it may fail to achieve market acceptance by physicians,
Page 36 - If we fail to comply with state and federal healthcare regulatory laws, we could face substantial pe
Page 37 - Product liability lawsuits against us could cause us to incur substantial liabilities and could limi
Page 38 - If we obtain approval to commercialize PDS0101 outside of the United States, a variety of risks asso
Page 39 - Risks Related to Our Dependence on Third Parties
Page 40 - Our relationships with customers and third-party payors will be subject to applicable anti-kickback,
Page 41 - Risks Related to Our Intellectual Property
Page 42 - We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or ou
Page 43 - General Market Risk Factors
Page 44 - We do not anticipate will pay any cash dividends in the foreseeable future.
Page 45 - Anti-takeover provisions under Delaware law could make an acquisition more difficult and may prevent
Page 46 - EXHIBIT INDEX
Page 47 - SIGNATURES
Subdocument 2 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
Subdocument 5 - EX-32.2 - EXHIBIT 32.2
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts